Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 7213 participants.
Also called NCT02313909
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 7,213 participants
- Registry
-
NCT02313909 -
2013-000768-27
-
- Other papers using this trial's data
- Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial
- Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial
- Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial
- Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis
- Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial
- Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial
- High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source
- Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial
- Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial
- Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial
- Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
- Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy
- Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Mexico, Poland, Portugal, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Türkiye, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT02313909. Randomized; quadruple masking; primary purpose prevention. Start 2014-12-23 (actual); primary completion 2018-02-15 (actual). Results posted on 2019-01-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
- Acronym
- NAVIGATE ESUS
- Condition
- Stroke
- Intervention (Drug)
- Rivaroxaban (Xarelto, BAY59-7939)
- Intervention (Drug)
- Acetylsalicylic acid (Aspirin, BAY1019036)
- Intervention (Other)
- Rivaroxaban-Placebo
- Intervention (Other)
- Aspirin-Placebo
- Lead sponsor
- Bayer
- Collaborator
- Janssen Research & Development, LLC
- Collaborator
- Population Health Research Institute
Record details
- Record id
cardio:ct-nct02313909- Content hash
ecf0dac72bd2930f7564479050048bfc92156be4d1098de36fdd4449ca05ed85